Is Melatonin Really Evil? What the Science and Sleep Supplement Market Actually Say

This is part of Ingredient Intelligence, a series tracking where the supplement market is going and what it means for your next SKU.

---

Few supplement ingredients have moved from hero to villain as quickly as melatonin. Once considered the obvious natural answer to a restless night, it is now facing increased scrutiny. Alarming headlines and social conversations raise questions about its safety, effectiveness, and potential long-term effects. But are these concerns grounded in science, or has melatonin become a misunderstood villain in the sleep supplement category?

The answer is less frightening and more nuanced than the headlines suggest. Melatonin plays a legitimate role in regulating the body’s sleep-wake cycle, with research supporting its use for jet lag and certain circadian rhythm conditions. Short-term use appears reasonably safe for many adults. However, questions remain about long-term nightly use, appropriate dosing, product consistency, and whether melatonin is the right solution for every sleep concern.

For supplement brands, the real risk isn’t melatonin itself. It’s allowing fear and misinformation to shape product strategy without understanding the science or shifting consumer preferences. Consumers are not abandoning melatonin, but they are expanding their expectations of sleep support. As melatonin-free products gain momentum, brands have an opportunity to rethink how they formulate, position, and differentiate their sleep portfolios.

The better question is not whether melatonin is good or evil. It is whether the ingredient fits the intended use, the formulation is supported by science, and the finished product delivers what the label promises.

The Sleep Market Is Growing Beyond Melatonin

Using those reported segment totals, melatonin-free products account for roughly 54% of the combined melatonin and non-melatonin tracked sales. The segments may include differences in assortment and distribution, so the figures should inform a portfolio decision rather than predict a specific launch outcome.

This is category diversification, not abandonment. One shopper may want a familiar product associated with the nighttime routine. Another may prioritize relaxation, a non-hormone proposition or a different morning-after experience. Brands can serve both without depicting either choice as unsafe or inferior.

What Is Melatonin, and Why Does Timing Matter?

According to the National Institutes of Health overview of melatonin, melatonin is a hormone produced in response to darkness and involved in coordinating the sleep-wake cycle. This makes its role fundamentally different from simply describing an ingredient as a universal sedative.

For product marketers, that distinction affects how a concept is built and explained. Use occasions, directions, timing and labeling must be considered together. A message that implies more milligrams always equals a better night is not an evidence-based product strategy.

Where the Evidence Fits

Evidence context	What it means for brands
Circadian timing and jet lag	Clinical findings are occasion-specific; avoid translating them into a universal nightly benefit.
Persistent adult insomnia	Professional guidelines do not support a blanket melatonin treatment message.
Short-term use	Generally well tolerated in many adults, but appropriate cautions still matter.
Long-term nightly use	Evidence gaps remain; avoid implying indefinite use is fully studied.

The American Academy of Sleep Medicine clinical practice guideline suggests clinicians not use melatonin to treat sleep-onset or sleep-maintenance insomnia in adults. That was a weak recommendation based on very low-quality evidence for the assessed regimen, not proof that melatonin is ineffective for every user or every occasion.

A clinical guideline about a diagnosed sleep disorder is not a template for supplement claims. Brand communications should stay with appropriately substantiated support for normal sleep-wake rhythms or occasional sleep-related needs, rather than implying treatment for persistent insomnia.

Why the Melatonin Backlash Feels So Loud

The sleep aisle meets three conditions that amplify controversy: widespread access, repeat use and highly personal expectations. A product that is familiar enough to be routine can also become the focus of concern when consumers hear new research findings or experience results that do not match expectations.

A 2026 CDC analysis of 2024 survey data found that 12.9% of U.S. adults reported using some type of sleep aid most days or every day in the preceding month. Within that group of measures, 5.7% used an over-the-counter medication or supplement with that frequency. These data describe sleep-aid behavior broadly, not melatonin-specific demand.

For brand teams, the opportunity is to replace a one-note sleep promise with sharper positioning. Consumers assess a product through its shopping cues, sensory experience, directions, intended benefit and perceived next-day fit. Even an ingredient with strong recognition still needs a clear reason to belong in a modern assortment.

What Do the Heart-Health Headlines Actually Show?

A preliminary American Heart Association conference analysis released in November 2025 reviewed health records for more than 130,000 adults with insomnia. In that observational dataset, recorded longer-term melatonin exposure was associated with a greater incidence of heart failure over five years. The reported comparison was 4.6% versus 2.7%.

The study did not demonstrate that melatonin caused heart failure. It was a conference abstract rather than a fully peer-reviewed manuscript at the time of the announcement. Recording of over-the-counter melatonin use may have been incomplete, and characteristics associated with insomnia and other health factors could affect comparisons.

This is exactly where evidence discipline becomes a brand advantage. The appropriate response is neither to dismiss a research signal nor to convert it into a frightening claim. Product teams should monitor emerging data, have safety and regulatory experts review labels and keep public messaging focused on substantiated, appropriate uses.

Product Quality Is Part of the Melatonin Story

Melatonin is often presented as a simple ingredient. Yet products containing low quantities of an active ingredient can create demanding manufacturing and testing questions, particularly across different dosage formats. Label accuracy is essential to the credibility of dose guidance.

In a 2017 analysis of commercial melatonin supplements, more than 71% of sampled products were outside a 10% range of the labeled content, and 26% contained detectable serotonin. One product showed lot-to-lot variability reaching 465%. These findings describe the sample tested, not the present-day industry-wide failure rate.

A separate 2023 JAMA analysis of 25 melatonin gummy products found 22 with inaccurate melatonin labeling. In gummies containing melatonin, measured amounts ranged from 74% to 347% of labeled content. Again, the finding is a caution about the studied products rather than a claim that every gummy has this issue.

What Brands Should Ask Their Manufacturing Partner

• How are raw-material identity, ingredient specifications and supplier documentation reviewed before release?
• Which potency and content-uniformity controls apply to the intended delivery format and dose?
• What do the finished-product Certificate of Analysis (CoA), stability program and specifications establish?
• How does GMP-certified manufacturing address blending, sampling, change control and batch-to-batch consistency?

A credible manufacturer, as the supplement contract manufacturing guide explains, helps connect each specification to a commercial outcome: fewer unpleasant surprises, more reliable repeat purchases and a defensible quality story. Testing and documentation should support the entire shelf-life proposition, not merely the first finished batch.

Melatonin-Free Does Not Mean Evidence-Free

For brands seeking innovation without melatonin, the strongest path is to define the desired support occasion before selecting ingredients. Relaxation, healthy sleep quality and support for a restful nighttime routine are related but distinct propositions. Each requires ingredient-specific substantiation and finished-product evaluation.

A melatonin-free formula may combine ingredients whose studies examine different endpoints. That does not mean their results automatically add together. It means custom supplement manufacturing should begin with a documented formulation rationale and a disciplined claim review.

Build the Formula Around Clearly Defined Roles

In an eight-week randomized study of Holixer holy basil extract, adults experiencing stress showed improvement on certain stress measures and subjective sleep outcomes versus placebo.^† These findings are specific to the studied extract, dose and population; they do not establish that all holy basil ingredients produce identical effects.

A 2025 randomized study of a standardized lime peel supplement included 80 adults over two weeks at 300 mg daily and reported improvements in measured sleep parameters.^† The published material was standardized, an important consideration when assessing whether a supplier ingredient is comparable to the ingredient in a trial.

A 2016 human investigation of oral GABA also reported shorter sleep latency and increased non-REM sleep.^† Brands should evaluate study size, intervention, dose, ingredient source and endpoints before translating such research into proposed claims. A sound branded ingredient strategy also recognizes that a name by itself is not proof of finished-formula efficacy.

A product concept that brings multiple components together will also need feasibility work. Ingredient interaction, capsule capacity, taste, stability, flow and packaging can change the commercial equation. The most differentiated formula is not necessarily the one with the longest Supplement Facts panel.

A Smarter Two-Lane Sleep Portfolio

Give Both Lanes a Common Quality Standard

Use consistent expectations for supplier qualification, identity, purity, specifications, manufacturing controls and release testing. Brands should also review how directions and product descriptions work together across e-commerce, retail shelf tags and educational material. Clarity at every touchpoint builds a more coherent portfolio.

Keep the Regulatory Boundary Clear

Under FDA guidance on structure/function claims, dietary supplement claims must be truthful, not misleading and supported by substantiation. Labels making covered structure/function claims have notification and disclaimer requirements. Claims suggesting that a supplement treats or prevents a disease cross a different regulatory line.

For sleep products, this means phrases such as “supports relaxation” or “supports healthy sleep patterns” require adequate substantiation, while positioning a supplement as a treatment for chronic insomnia, sleep apnea or a cardiovascular condition is not appropriate. Ingredient research that happens to involve people with a clinical condition does not automatically authorize a disease claim for a finished supplement.

Claim review should include packaging, paid media, product pages, influencer materials and the implied message created by surrounding copy. The goal is not to make the language timid. It is to give buyers a benefit story that marketing, quality and regulatory teams can all defend.

What This Means for Dietary Supplement Brands

Brands that want to compete in sleep now have to run two lanes, melatonin and melatonin-free, and defend both on evidence and on quality. That makes the choice of a dietary supplement contract manufacturer a strategy decision, not a purchasing one. Here are the most important considerations for your brand:

Market Opportunity: Reliance-supplied SPINS data put melatonin-free sleep products at $548.5 million, growing 3.0%, against $465.1 million and 1.3% for melatonin and melatonin-based formulas. That supports building complementary lines for different shopper occasions rather than treating the choice as either-or. Because the segments may differ in assortment and distribution, the figures should inform a portfolio decision, not predict a single launch.

Formulation: Melatonin products carry a low quantity of an active ingredient, which creates demanding manufacturing and testing questions, and a 2023 JAMA analysis of 25 gummy products found measured melatonin ranging from 74% to 347% of the labeled amount. Content uniformity, potency controls for the chosen delivery format and stability testing that supports the whole shelf life, not only the first finished batch, belong in the specification. In a melatonin-free blend, ingredient interaction, capsule capacity, taste and flow need feasibility work too, since studied ingredients do not automatically add together.

Branded Ingredients: Holixer holy basil extract (studied at 250 mg daily) and Benesomno standardized lime peel (studied at 300 mg daily) carry their evidence only when the finished product matches the studied extract, standardization and dose. Supplier documentation and material identity should be confirmed before formulation, because a branded ingredient name by itself is not proof of finished-formula efficacy.

Brands that settle the portfolio, the specifications and the ingredient documentation together are the ones that can move both lanes from brief to shelf with a story that holds up.

Frequently Asked Questions About Melatonin and Sleep Supplement Development

What Sets Reliance Apart for Sleep Supplement Brands?

Reliance already manufactures sleep products in both lanes this post describes, so brands can start from proven formulas instead of a blank page. Our cognitive, mood and sleep formulas include melatonin at 3 mg, 5 mg and 10 mg, in lozenge and chewable formats as well as standard doses, alongside melatonin-free options such as GABA and dedicated sleep and relaxation formulas.

As a turnkey supplement contract manufacturing partner, Reliance supports both lanes with:

• Stock formulas for speed to market, ready for your label while a custom concept is in development
• Custom formulation and R&D for melatonin-free concepts built around a defined need state
• In-house testing for identity and potency, with full CoA transparency
• Multi-format production across capsule, tablet, powder, softgel and chewable formats
• More than 40 years of manufacturing experience, from the first brief through commercialization

^†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.